ImetelChat

So the thesis for the stock price is that it's quite likely that nothing will happen for at least the next 6 months at least, possibly even 12 Full enrollment, but I doubt that will give any real rise, as dilution will put people off. What I don't understand is the interim analysis being scheduled s...

Gofundme allows the option to only accept the donation if the target gets reached. Could be worth doing. This site has been the only point of sanity for discussion on the medical points and share price for these past few years and my hair will lose the last tiny bit of colour if the next 18 months d...

I doubt we will get any meaningful good news from the coming EHA based on scarlet saying the 2 abstracts are based on the P2 data. Extensions to survival ofc is amazing, just not currently for the share price. Late breaking abstracts vaguely possible, but as they seem to be playing the long game so ...

A quick google shows that they have to come up with lots of different names and then the FDA and other bodies then decide which one they will use.

Probably best to trade mark all of the ones they put forward so there isnt a problem later

Voting Yes is the only reasonable response.

They need more money in these uncertain times to get them through commercialization, more possibly more covid delays, possibly to kick off an AML trial judging by the size of the dilution.

"Add to the list We are looking at companies to acquire"

Yes, I think that one is being saved as the nail in the coffin for any positive news that may dare risk its head.
Do we know how the extra shares will be sold to the market yet?

If, as previously stated, we don't get any interm results at EHA or ASH, then I can't see anyone one having confidence in this in the long term. If the result are anything like the P2 then at this point they should be able to prove it. Leave it for another 2 years would be not good for shareholders ...

I'm quite surprised at the overwhelmingly negative reaction from the CC. Apart from the stabbing in the back from announcing a dilution immediately after the call. Do they not have a PR person that considers that this is a massively slap in the face that could have been easily avoided? More dilution...

Hi all, Sorry for the none science-related question, however, it's the best forum to address the strange activity of the last week and you are all keen observers. I'm rather too heavily invested in Geron for my own good and keep a close eye on it( I know, watched toast and all that) however the larg...

Just for ref, I think this is what is being talked about.

https://charts.stocktwits.com/productio ... 774241.png

Just for ref

Forth!

Although I think that scarlet will surprise us all way before 2022. Be that with more financing, sales to institutions with little notice so that they can fund an AML trial, or something. It feels like there is ahead of steam with developments. Fanciful wishful thinking I know.

The large number of Options that have been open on Geron for Jan 2021 all summer is intriguing. Some possible event then, although no idea what it could be.

I've been trying to confirm that the abstracts will be available on the 5th, however it's either been removed or just existing in my lockdown imagination. Checking the ASH website says that this year notifications that an abstract has been accepted can be sent up to the 12 November, so I guess that ...

The abstracts are online the same day as the geron earnings. Read into it what you will.

Crossover would only be allowed after they have overwhelming results and it would be unethical to leave people on a placebo. Which would basically mean that the drug is approved and they are going through the formalities. I doubt this would be something we would get much information from scarlet on....

Mentioning the Ash abstracts in the last conference was unusual and is possibly pointing to the fact that they already know.

I would still dearly love to hear when this is going to be available for compassionate use. It's an old JnJ wound that still hasn't healed. If the drug is as amazing as we hope then alot of people have suffered over the last years in this not being out there. But going forward, at what point could t...

Other options are more dilution and then an reverse split to keep it above a dollar.

While none of us want to consider this seriously it's still an option that gives me nightmares.

Timing?

If they wait and see what the results are like in the current trial and the nature of what (hopefully) will be announced this month they would know more about what they are buying.

If it is a normal P3 then we have another year or two before this could be acquired.